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ABSTRACT
AMD3100 inhibits the interaction between SDF-1 and CXCR4, and rapidly mobilizes hematopoietic progen-
itors for clinical transplantation. However, the repopulating function of human cells mobilized with AMD3100
has not been characterized in comparison to cells mobilized with granulocyte-colony stimulating factor
(G-CSF) in the same donor. Therefore, healthy donors were leukapheresed 4 hours after injection with
AMD3100; after 10 days of drug clearance the same donor was mobilized with G-CSF, allowing a paired
comparison of repopulation by mobilized cells. Transplantation of mononuclear cells (MNC) or purified
CD34 cells was compared at limiting dilution into NOD/SCID mice. Human AMD3100-mobilized MNC
possessed enhanced repopulating frequency in comparison to G-CSF-mobilizedMNC from paired donors, and
purified CD34 progenitors were at least as efficient as the G-CSF mobilized cells. The frequencies of
NOD/SCID repopulating cells (SRC) were 1 SRC in 8.7 106 AMD3100-mobilized MNC compared to 1 SRC
in 29.0  106 G-CSF-mobilized MNC, and 1 SRC in 1.2  105 AMD3100-mobilized CD34 cells compared
to 1 SRC in 1.8  105 G-CSF-mobilized CD34 cells. Hematopoietic differentiation of transplanted progen-
itors was similar after AMD3100 or G-CSF-mobilization. Thus, AMD3100 mobilized peripheral blood rep-
resents a rapidly obtained, highly repopulating source of hematopoietic progenitors for clinical transplantation.
© 2007 American Society for Blood and Marrow Transplantation
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AMD3100 Mobilized CD34 Cell Repopulation 399NTRODUCTION
Mobilized peripheral blood (MPB) hematopoietic
rogenitor cell (HPC) transplantation has emerged as
he preferred strategy for the treatment of hematologic
alignancies. Granulocyte-colony stimulating factor
G-CSF) is the “gold standard” to mobilize HPC from
he bone marrow (BM) to the peripheral blood for leu-
apheresis and transplantation [1,2]. After 4-5 days
-CSF effectively increases the total yield of CD34
ells available for transplantation. In comparison to BM
ransplantation (BMT), the increased number of infused
ells after G-CSF mobilization positively inﬂuenced
arrow recovery and reduced the time to neutrophil and
latelet production [3,4]. However, G-CSFmobilization
emonstrates broad interindividual variations in circu-
ating progenitor cell numbers [5,6]. At suboptimal
PC doses hematopoietic recovery becomes signiﬁ-
antly delayed or incomplete, and may result in pro-
onged neutropenia, bleeding, increased infectious
omplications, increased hospital stay, and even graft
ailure [7-10]. As a consequence, alternative mobiliza-
ion strategies have been sought to safely increase
D34 cell isolation, particularly in patients heavily
retreated with chemotherapeutic agents, who fail
PC mobilization using G-CSF mobilization [11,12].
Interactions between the chemokine receptor
XCR4 and its cognate ligand, CXCL12 or stromal-
erived factor-1 (SDF-1), regulate the survival [13-
5], directed chemotaxis [16-19], and engraftment of
D34 HPC [20,21]. CXCR4/SDF-1 interaction is
lso involved in the retention of hematopoietic stem
ells (HSC) within the BM [22,23]. Thus, pharmaco-
ogic interference in the axis between marrow-derived
DF-1 and CXCR4 expressed on CD34 human
SC or HPC has been investigated as a mobilization
trategy [13,20,24,25]. Subsequently, AMD3100 has
een shown to reversibly bind CXCR4 and inhibit the
nteraction between SDF-1 and CXCR4 within the
M microenvironment resulting in the mobilization
f CD34 cells into the circulation of healthy volun-
eers and in cancer patients who have been treated
ith chemotherapeutic agents [11,26]. In these stud-
es, AMD3100 was well tolerated without signiﬁcant
oxicity. The collection of total CD34 cells was com-
arable between individuals mobilized 4 hours after a
ingle injection of AMD3100 (240 g/kg) and indi-
iduals mobilized by a 5-day treatment regimen with
-CSF [27]. In a randomized trial, the combination of
-CSF treatment with AMD3100 administration re-
ulted in superior CD34 cell mobilization when
ompared to G-CSF alone, and patients receiving
MD3100  G-CSF autologous transplants for non-
odgkins lymphoma and multiple myeloma dem-
nstrated strong early engraftment with recovery
f neutrophil production between days 10 and 13
12]. Collectively, these studies demonstrated that sMD3100 is a safe and effective agent for the rapid
obilization of CD34 cells in healthy donors and in
atients who had received prior chemotherapy. How-
ver, these clinical studies did not address the repop-
lating capacity of mobilized CD34 cells for engraft-
ent and reconstitution potential after AMD3100
reatment alone, without G-CSF administration, and
hat was the goal of the current study.
Preliminary preclinical evaluation of the engraft-
ng capacity of AMD3100-mobilized cells has been
eported recently in murine, canine, and primate
ransplantation models [28-30]. Both autologous and
llogeneic AMD3100-mobilized HPC led to immedi-
te, long-term engraftment in dogs and rhesus ma-
aques after lethal irradiation [28,30]. Broxmeyer and
olleagues [29] showed that AMD3100 induced rapid
obilization of murine HPC and synergistically aug-
ented G-CSF mobilization. AMD3100 was capable
f mobilizing long-term repopulating murine stem
ells that engrafted primary and secondary recipients.
n studies performed with human cells, the greatest
umber of NOD/SCID repopulating cells (SRC)
ere found in donors mobilized by a combination of 5
ays G-CSF followed by 1 injection of AMD3100,
ompared to the traditional regimen of 5 days G-CSF
lone [29]. However, these studies were normalized
or the number of SRC/kg donor body weight, and did
ot include human cell chimerism information for
onors mobilized with AMD3100 alone, which we
ssessed in the current study. In rhesus macaques,
D34 cells mobilized by AMD3100 expressed higher
XCR4 and VLA-4 expression, and demonstrated
ncreased levels of gene marking than G-CSF mobi-
ized samples. These data demonstrate that AMD3100
obilized HPC with intrinsically different character-
stics than HPC mobilized with G-CSF [24].
In the current studies, we directly compared the
OD/SCID repopulating function of cells from the
ame normal donors who were rapidly mobilized (4
ours) by AMD3100 versus cells mobilized after 5
ays of G-CSF treatment. The SRC values for both
D34 cells and total MNC from the mobilized
roducts were analyzed for each donor using limiting
ilution and Poisson statistics. A total of 6 donors
ere leukapheresed after a single injection of 240
g/kg AMD3100. After 10 days of drug clearance, the
ame donor was mobilized with G-CSF, allowing a
aired comparison of the repopulating function of
ells mobilized by the 2 agents. The studies demon-
trated that human AMD3100 puriﬁed MNC possess
nhanced repopulating frequency, on a cell-per-cell
asis, compared to G-CSF mobilized cells from the
ame donor. However, puriﬁed CD34 cells from
MD3100-mobilized peripheral blood demonstrated
more modest increase in repopulating function.
hus, AMD3100-mobilized peripheral blood repre-
ents a rapidly obtained and highly functional source
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D. A. Hess et al.400f repopulating hematopoietic stem cells for clinical
ransplantation procedures.
ATERIALS AND METHODS
onor Selection and Leukapheresis
Healthy donors for allogeneic transplantation
ere accrued as part of a clinical trial evaluating the
tility of AMD3100 for the mobilization and trans-
lantation of HPC in patients with advanced malig-
ancies. Clinical samples were obtained at the Wash-
ngton University School of Medicine (St. Louis, MO)
ccording to protocols approved by the Human Sub-
ects Committee. Donors received 1 subcutaneous in-
ection of 240 g/kg AMD3100 (AnorMED, Langley,
C), followed by leukapheresis beginning 4-6 hours
fter drug treatment. Ten to 15 mL of the total leu-
apheresis product (representing 2-3% of the total
eukapheresis product) was reserved for cellular pro-
essing and transplantation experiments. After 10 days
f drug clearance, the same donors were mobilized
ith 5 days subcutaneous injection of 10 g/kg/day
-CSF, and leukapheresed on day 5.
uman Cell Purification
Blood and leukapheresis aliquots for experiments
ere processed immediately after harvest. Erythrocyte
ontamination was depleted by washing in human red
ell lysis buffer (0.8% ammonium chloride solution,
tem Cell Technologies, Vancouver, BC, Canada),
hen cells were counted and divided for MNC trans-
lantation or further puriﬁcation of CD34 progeni-
ors. Human CD34 cells were puriﬁed by positive
election with a Magnetic Afﬁnity Cell Selection
MACS) CD34 isolation kit (Miltenyi Biotec, Auburn,
A). The purity of isolated cells was quantiﬁed by
ACS analysis (86% for all experiments).
low Cytometry Analysis
Before and after CD34 cell selection cells were
tained with antihuman monoclonal antibodies for
ow cytometric analysis of cell surface markers ex-
ressed on primitive human HSC subsets, as well as
-lymphocyte, B-lymphocyte, and myeloid subsets.
wo to four parameter ﬂow cytometric analysis was
erformed on a Coulter FC-500 ﬂow cytometer (Beck-
an-Coulter, Miami, FL) and analyzed using Cytom-
cs RXP analysis software. To prepare cells for ﬂow
ytometric analysis, harvested MNC or freshly puri-
ed CD34 cells were blocked using CD16/32w
cIII-receptor blocker (Pharmingen, San Diego, CA).
elevant isotype controls against human IgG1/2a
X0969, DakoCytomation, Glostrup, Denmark) were
erformed on all samples. The following antihuman
onoclonal antibodies were used for phenotype anal-
sis of human progenitor cells (CD34-FITC, CD38- cE, and CD133-APC (Miltenyi Biotechnology, Au-
urn, CA), human T-lymphocytes (CD4-FITC,
D8-PE, and CD3-APC), human B-lymphocytes
CD20-FITC and CD19-PE), and human myeloid
ells (CD14-FITC, CD33-PE) (all antibodies were
rom Beckton Dickinson, San Jose, CA, unless other-
ise indicated).
ransplantation and Analysis of Human
ell Engraftment
NOD/SCID mice were obtained from Jackson
aboratories, Bar Harbor, ME, and were bred at the
nimal facilities of the Washington University School
f Medicine. The Animal Studies Committee ap-
roved all animal experiments. Human mobilized pe-
ipheral blood MNC and puriﬁed CD34 cells were
ransplanted by tail vein injection into 8-10-week,
ublethally irradiated (300 cGy) NOD/SCID mice. A
ange of human MNC (106-40 106 cells) or puriﬁed
D34 cells (2 104-1 106 cells) were injected into
uadruplicate mice at a minimum of 3 different doses
er donor to allow direct statistical comparison of
uman cell engraftment between AMD3100 and G-
SF mobilization at limiting dilution. Seven to 8
eeks posttransplantation, BM, spleen, and peripheral
lood were harvested and labeled using monoclonal
ntibodies for the human pan-leukocyte marker
D45-APC, in combination with CD38-PE or iso-
ype controls (BD) as previously described [31,32].
ells were analyzed on a Coulter FC-500 ﬂow cytom-
ter (Beckman-Coulter). An engrafted mouse for SRC
requency quantiﬁcation was deﬁned as 0.2% hu-
an CD45/CD38 coexpressing cells and 10,000
vents were recorded per mouse. Low levels of human
ngraftment (0.2%) were conﬁrmed by P17H8 PCR
32]. Engrafted mouse BM (2% CD45) was further
nalyzed for the frequency of B-lymphoid cells
CD20-FITC, CD19-PE), myeloid cells (CD14-
ITC, CD33-PE), T-lymphoid cells (CD4-FITC,
D8-PE), and primitive cells (CD34-FITC, CD38-
E) (all antibodies, Beckton Dickinson).
tatistics
Levels of human engraftment were reported as the
ean  SEM for mice grouped according to trans-
lanted cell numbers and compared using a Student=s
-test. SRC analysis was performed using the single-
it model and Poisson statistics at limiting dilution
ith 95% conﬁdence intervals. Statistical analysis
oftware was provided by Stem Cell Technologies,
ancouver, BC, Canada.
ESULTS
Mobilization of human leukocytes and CD34ells by AMD3100 and G-CSF was done in normal,
h
m
h
v
A
m
w
i
t
l
m
v
u
d
c
(
w
w
1
G
i
3
m
p
b
w
G
c
c
i
i
e
i
b
A
c
f
r
p
f
p
t
w
(
C
p
9
w
t
G
l
o
w
r
C
c
b
r
f
p
C
m
E
I
d
c
A
t
t
ﬂ
u
(
i
C
s
p
a
A
d
t
F
t
w
m
s
f
c
A
w
p
o
c
p
m
f
c
p
t
p
b
AMD3100 Mobilized CD34 Cell Repopulation 401ealthy donors. Liles et al [26], followed by Brox-
eyer et al [29], were the ﬁrst to report that functional
uman HPC were effectively mobilized in healthy
olunteers within 4-6 hours after injection of
MD3100. These investigators and others have aug-
ented mobilization and collection of CD34 cells
hen G-CSF treatment was combined with a single
njection of AMD3100 [12,27]. We directly assessed
he engraftment capacity of AMD3100 and G-CSF
eukapheresis products obtained following sequential
obilization by both agents in the same healthy indi-
idual. The mobilization protocol is illustrated in Fig-
re 1.
AMD3100 and G-CSF administration both in-
uced a signiﬁcant increase in white blood leukocyte
ounts (WBC), in comparison to baseline controls
*P  .001) (Table 1). Total blood leukocyte counts
ere increased 3-fold from baseline in peripheral blood
ithin 4 hours of AMD3100 administration (6.5 0.3
03 vs 19.1  0.6  103 WBC/mL), whereas 5 days of
-CSF administration induced a greater than 5-fold
ncrease from baseline (7.0  0.5  103 vs 39.0 
.0  103 WBC/mL) (*P  .001). Overall, G-CSF
obilized 2-fold higher numbers of leukocytes, com-
ared to AMD3100 administration (P  .001). Red
lood cell, platelet, and hemoglobin concentrations
ere not altered from baseline by AMD3100 or
igure 1. Study design for the treatment of healthy human volun-
eers with AMD3100 followed by G-CSF. Normal donors (n  6)
ere recruited for allogeneic BM transplantation and HPC were
obilized using both AMD3100 and G-CSF administration in the
ame individual. Baseline peripheral blood samples were drawn
rom each healthy donor prior to AMD3100 injection for CBC
ounts and differential. Each donor was administered 240 mg/kg
MD3100 at the beginning of the study protocol and leukapheresis
as collected 4-6 hours after injection. After a 10-day washout
eriod, the same donors were mobilized with 5 days administration
f G-CSF at 10 mg/kg/day. Leukapheresis products were then
ollected on the 5th day of rhG-CSF administration. Leukapheresis
roducts from both leukapheresis protocols were analyzed for the
obilization of total leukocytes and total CD34 cells. An aliquot
rom each leukapheresis product (10-15 mL) from each donor were
ollected for phenotypic analysis of HPC markers, CD34 cell
uriﬁcation, and for the quantiﬁcation of SRC frequency after
ransplantation into sublethally irradiated NOD/SCID mice. This
rotocol design allowed for a direct comparison of HPC mobilized
y each agent in the same individual.-CSF administration (data not shown). As expected, pomplete blood count (CBC) differentials also indi-
ated an increased frequency of neutrophils (P  .05)
n G-CSF leukapheresis, with a concomitant decrease
n lymphocyte frequencies (data not shown). How-
ver, AMD3100 administration did not result in an
ncreased frequency of granulocyte or neutrophil mo-
ilization. The rapid mobilization demonstrated by
MD3100 is advantageous and cost effective in a
linical setting.
Determination of total CD34 cell number and
unction allows prediction of the rate of hematopoietic
ecovery in transplanted individuals. Table 1 com-
ares the mobilization of total CD34 cells harvested
rom paired healthy donors, allowing for a direct com-
arison of mobilization efﬁciency for both agents in
he same individual. Total CD34 cell mobilization
as 2-fold higher in the G-CSF leukapheresis product
6.2  3.2  106 CD34 cells/kg or 1672  768
D34 cells/L), compared to the AMD3100 leuka-
heresis product (2.9  1.0  106 CD34 cells/kg or
28  351 CD34 cells/L). Although these data
ere not statistically signiﬁcant in our study design,
he modest increase in CD34 cell mobilization by
-CSF may reduce the requirement for secondary
eukapheresis procedures by assuring optimal accrual
f target HPC (5  106 CD34 cells/kg body
eight) previously associated with rapid neutrophil
ecovery in transplanted patients [5,6]. However,
D34 cells from alternate sources [BM or umbilical
ord blood (UCB)], as well as CD34 cells mobilized
y different agents may demonstrate widely variable
epopulating functions in vivo [33,34]. Thus, we per-
ormed a detailed comparison of the NOD/SCID re-
opulating function of total MNC and puriﬁed
D34 cells collected from the same donors by both
obilization regimens.
xpression of Primitive HPC Cell Surface Markers
s Similar in AMD3100 and G-CSF Leukapheresis
Prior to the transplantation of MPB into immune-
eﬁcient NOD/SCID mice, we performed a detailed
ell surface marker analysis of HPC collected by
MD3100 or G-CSF treatment, to directly compare
he frequencies of primitive hematopoietic cells con-
ained within injected cohorts. Figure 2 shows the
ow cytometric analysis of lysed leukapheresis prod-
ct MNC (Figure 2A-D), or puriﬁed CD34 cells
Figure 2E-H) for the cell surface expression of prim-
tive hematopoietic markers CD34 with CD133, or
D34 with CD38. These markers represent the gold
tandard for predicting NOD/SCID repopulating
henotype in vivo [32,35-38]. CD34 was expressed on
pproximately 0.5%-1.0% of total leukocytes after
MD3100 or G-CSF administration. There was no
ifference in the frequency of CD34 expression be-
ween paired AMD3100 and G-CSF mobilized sam-
les. Likewise, the percentages of coexpression of
Table 1. Blood Cell Counts, Total CD34 Cell Enumeration, and SRC Frequencies from Individual Donors after Administration of AMD3100 (240 g/kg) or G-CSF (10 g/kg/day)
Donor
No.
Mobilizing
Aagent
WBC, 103/mL
Total CD34,
106 cells/kg
Total CD34,
Cells/L
SRC Frequency,
106 MNC
95% Confidence
Interval, 106
MNC
SRC Frequency,
103 CD34
95% Confidence
Interval, 103
CD340 Hours At Leuk.
1 AMD3100 7.6 17.8 1.05 260 1 in 3.5 1.4-9.1 1 in 79 30-211
G-CSF 9.2 40.1 1.72 350 1 in 7.3 3.4-15.8 1 in 101 44-229
2 AMD3100 5.5 21.1 0.40 320 1 in 34.0 10.5-110.6 1 in 55 18-174
G-CSF 5.7 45.2 2.50 1210 0% eng.* 0% eng.* 0% eng.* 0% eng.*
3 AMD3100 5.6 18.9 1.49 470 1 in 7.9 3.0-20.6 1 in 40 9-178
G-CSF 6.3 30.0 3.29 970 1 in 69.0 16.6-286.2 1 in 234 93-590
4 AMD3100 7.1 19.7 4.56 1290 100% eng.† 100% eng.† 1 in 35 12-101
G-CSF 7.8 43.3 ND ND ND‡ ND† ND‡ ND‡
5 AMD3100 7.0 19.5 6.25 2510 1 in 7.2 2.9-17.6 1 in 158 67-378
G-CSF 6.5 45.8 18.7 4690 1 in 19.8 8.0-48.7 1 in 97 39-242
6 AMD3100 6.1 17.4 1.97 720 1 in 11.0 6.9-17.6 1 in 104 64-172
G-CSF 6.6 29.4 5.01 1140 ND§ ND§ 1 in 109 61-179
Mean AMD3100 6.50.3 19.10.6* 2.91.0 928351 1 in 8.7* 6.0-12.7 1 in 117 75-181
G-CSF 7.00.5 39.03.0* 6.23.2 1672768 1 in 29.0 17.5-47.9 1 in 177 113-275
ND indicates not determined; Eng., engrafted; SRC, NOD/SCID repopulating cells; g-CSF, granulocyte-colony stimulating factor.
Blood for CBC counts was drawn from each donor before drug administration and just prior to leukapheresis (4 hours after injection of AMD3100 and on Day 5 of G-CSF treatment). CD34 cell
enumeration was performed on collected leukapheresis product. AMD3100 and G-CSF administration induced a signiﬁcant increase in blood leukocyte counts (WBC) compared to baseline controls
(*P  .001). Red blood cells (RBC), hemoglobin, platelets, and hematocrits were not altered by AMD3100 or G-CSF administration. Total leukocyte and total CD34 cell mobilization was increased
approximately 2-fold in G-CSF versus AMD3100 leukapheresis.
For each paired donor, sublethally irradiated (300 cGy) NOD/SCID mice were transplanted using a minimum of 3 cell concentrations for MNC (doses  1  106-40  106 cells) and puriﬁed CD34
cells (doses  0.2  105-106 cells) at limiting dilution using 3-5 mice per dose. SRC frequencies and 95% conﬁdence intervals were calculated by Poisson statistics using the single-hit model. Mice
were considered engrafted if the level of human cell engraftment in the murine BM was 0.2% CD45 and CD38. Human cell engraftment was conﬁrmed by PCR for human DNA sequences
(P17H8) for mice demonstrating 0.1% human cells by ﬂow cytometry.
*0% eng. G-CSF MPB MNC (n  10) and puriﬁed CD34 cells (n  10) from donor 2 produced no engraftment in transplanted animals. Thus, calculation of SRC frequency could not be performed.
†100% eng. AMD3100 MPB MNC from donor 4 showed signiﬁcant human cell engraftment (1.5% CD45 and CD38) in 100% of transplanted mice (dose range 5 106-40 106 MNC, n 9).
Thus, calculation of SRC frequency by Poisson statistics could not be performed.
‡ND. After G-CSF administration, donor 4 required a catheter for leukapheresis and G-CSF MPB was not used for animal experiments.
§ND. After G-CSF administration, donor 6 leukapheresis was used for CD34 cell selection only.
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AMD3100 Mobilized CD34 Cell Repopulation 403D34 with or without CD133, or CD34 with or
ithout CD38 were similar after comparison of
ooled data from 5 paired individual donors. How-
ver, G-CSF leukapheresis contained a signiﬁcantly
ncreased (P  .05) frequency of primarily differenti-
ted CD34	CD38 cells [32], indicating that the in-
reased total yield of CD34 cells after G-CSF ad-
inistration resulted from the maintenance of CD34
ell frequency combined with increased overall sample
ellularity (Table 1).
Positive selection of cells expressing the CD34
urface antigen resulted in 86% purity, conﬁrmed
y ﬂow cytometry for processed samples from each
aired donor (range 86%-96% CD34 cells, n  5).
n addition, there were no comparative differences in
he frequency of cells expressing CD34, CD133, or
D38 after CD34 cell selection in paired AMD3100
nd G-CSF mobilized samples (Figure 2E-H). Thus,
ransplanted puriﬁed CD34 cells mobilized by
MD3100 or G-CSF administration displayed equiv-
lent phenotypes at the time of injection into NOD/
CID mice. This allowed a direct functional compar-
son of the repopulating capacity of MNC and CD34
ells harvested after AMD3100 or G-CSF mobiliza-
ion in each donor.
OD/SCID Repopulating Cells Are Present at a
ignificantly Higher Frequency in AMD3100
obilized, Compared to G-CSF Mobilized
eripheral Blood Mononuclear Fractions from the
ame Donor
Transplantation of human stem cell populations at
imiting dilution into immune-deﬁcient mice is used
s a quantitative assay to calculate the relative fre-
uency of primitive SRC using Poisson statistics with
he single hit model [32,33,36,37,39]. Wang et al [33]
sed these statistical methods to calculate the relative
requencies of stem cells isolated from human UCB
1 SRC in 9.3  105 cells), bone marrow (1 SRC in
.0  106 cells), and from G-CSF mobilized periph-
ral blood (1 SRC in 6.0  106 cells) after i.v. trans-
lantation. Likewise, this standardized assay has been
sed to compare stem and progenitor cell repopulat-
ng frequencies from various stem cell subpopulations
sing a variety of puriﬁcation methods exploiting cell
urface markers and functional activities [32,34,39].
ere, we employed the quantitative SRC assay to
ompare the frequency of repopulating cells from
MD3100 and G-CSF mobilized samples for unfrac-
ionated leukapheresis MNC and puriﬁed CD34
ells from 6 paired individuals receiving each mobiliz-
ng agent as described in Figure 1. To optimize anal-
sis using Poisson statistics, sublethally irradiated (300
Gy) NOD/SCID mice were transplanted by i.v. in-
ection at a minimum of 3 cell concentrations for
NC (doses  1  106-40  106 cells) and CD34igure 2. Comparison of primitive hematopoietic cell surface
arker expression on AMD3100 and G-CSF mobilized cells.
aired human MPB MNC or puriﬁed CD34 cell populations were
nalyzed for the coexpression of CD34 with CD133, or CD34 with
D38 prior to functional analysis. (A-D) Unpuriﬁed leukapheresis
NC demonstrated a low frequency of CD34 cells (1%). Com-
arison of AMD3100 versus G-CSF mobilized cells demonstrated
o differences in the frequencies of cells expressing primitive phe-
otypic markers. However, G-CSF leukapheresis products (n  5)
ontained a signiﬁcantly greater (P  .01) frequency of mature
D34	CD38 cells, compared to AMD3100 leukapheresis prod-
cts (n  5). (E-H) After CD34 positive selection, the puriﬁed cells
ere86% CD34. CD34-puriﬁed cells showed a high proportion
f CD38 progenitors and cells with primitive (CD34CD38	 or
D34CD133) phenotypes. Comparison of AMD3100 versus G-
SF mobilized CD34 cells demonstrated no signiﬁcant differ-
nces in the frequencies of cells expressing primitive phenotypic
arkers. Phenotypic analysis of puriﬁed CD34 cells was per-
ormed after AMD3100 and G-CSF mobilization in paired individ-
uriﬁed cells (doses  0.2  105-1  106 cells) using
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D. A. Hess et al.404-5 mice per dose. This strategy achieved successful
uman engraftment in multiple mice, without a situ-
tion where 0% or 100% of the mice were engrafted,
circumstance where Poisson statistics cannot be per-
ormed.
Figure 3 demonstrates the ﬂow cytometric detec-
ion of human cell engraftment in the BM of mice
njected with 2  107 MNC from AMD3100 and
-CSF MPB from donor 1. Injected mouse BM,
igure 3. Detection of human cell engraftment in the BM of NOD
epresentative ﬂow cytometric analysis of NOD/SCID mice transp
D-F) from donor 1. Mouse BM, spleen, and peripheral blood sampl
n BM was detected by ﬂow cytometry using the coexpression of t
requencies were 0.1% in nonengrafted controls (insets). BM engr
rom AMD3100 MPB (1.8 0.5%, n 5) compared to an equivalen
ngraftment in the BM of NOD/SCID mice transplanted with AMD
rom the same donor. Mice were considered engrafted if the frequen
erformed on mouse engraftment data to calculate the SRC frequ
obilization in each donor.pleen, and peripheral blood were analyzed for human mell engraftment 7-8 weeks after transplantation. Mu-
ine samples were analyzed for the expression of the
uman pan-leukocyte marker CD45 (Figure 3A, R1)
nd for the expression of the human leukocyte differ-
ntiation marker CD38 (Figure 3B, R2). R1 and R2
requencies were 0.1% in nonengrafted controls
Figure 3, insets). The overall level of human cell
ngraftment was quantiﬁed by ﬂow cytometry for the
oexpression of CD45 and CD38. An engrafted
mice transplanted with MNC from AMD3100 or G-CSF MPB.
with 2  107 MNC after AMD3100 (A-C) or G-CSF mobilization
harvested 7-8 weeks after transplantation. Human cell engraftment
leukocyte marker CD45 (R1) and human CD38 (R2). R1 and R2
t was increased (*P  .05) in mice transplanted with 2  107 MNC
from G-CSF MPB (0.2 0.1%, n 5). (G) Comparison of human
PB MNC (n 15, Œ) or G-CSF MPB MNC (n 15, ) isolated
uman cells was 0.2% CD45 and CD38. Poisson statistics were
limiting dilution for cells derived from AMD3100 versus G-CSF/SCID
lanted
es were
he pan-
aftmen
t dose
3100 M
cy of h
ency atouse was deﬁned as 0.2% human CD45/CD38
c
.
A
i
M
c
A
p
c
p
f
2
G
c
w
1
d
o
q
(
v
t
d
o
S
9
t
t
a
s
t
g
s
1
c
m
S
p
t
e
w
e
s
w
p
M
e
5
C
(
s
c
n
P
p
T
v
m
G
l
m
c
a
e
p
h
(
d
h
s
5
v
w
a
p
a
c
F
i
c
T
a
S
c
t
h
m
n
h
c
C
o
s
i
p
o
i
(
g
h
c
T
m
p
t
h
w
n
e
AMD3100 Mobilized CD34 Cell Repopulation 405ells. BM repopulation was signiﬁcantly increased (*P
05) in mice transplanted with 2  107 MNC from
MD3100 MPB (1.8  0.5%, n  5) (Figure 3A-C),
n comparison to an equivalent dose from G-CSF
PB (0.2  0.1%, n  5) (Figure 3D-F). The in-
reased level of engraftment of transplanted
MD3100 cells corresponds to the increased in vitro
rogenitor capacity of cells mobilized by AMD3100 in
omparison to G-CSF that has been previously re-
orted [26,29].
A total of 30 mice were transplanted with MNC
rom donor 1, with cell doses ranging from 1  106 to
0  106 cells isolated after AMD3100 (n  15) and
-CSF (n  15) mobilization (Figure 1G). Mice were
onsidered engrafted if the frequency of human cells
as 0.2% CD45 and CD38. Transplantation of
06, 107, or 2  107 AMD3100-mobilized MNC pro-
uced engraftment in 3 of 5 mice, 4 of 5 mice, and 5
f 5 mice, respectively, corresponding to an SRC fre-
uency of 1 SRC in 3.5 106 cells by Poisson statistics
Table 1). Mice that did not receive a full dose by tail
ein injection were excluded from the analysis. Similar
o previously reported SRC frequency [27], equivalent
oses from G-CSF MPB produced an SRC frequency
f 1 SRC in 7.3  106 cells. Although the calculated
RC frequencies were not statistically different using
5% conﬁdence intervals for this donor (Table 1),
hese analyses provided a representative example for
he in vivo functional comparison of HPC isolated
fter mobilization with AMD3100 and G-CSF in the
ame individual. Similar analysis was performed using
he MNC from 6 individual donors, and pooled en-
raftment data from paired donors provided greater
tatistical power and an overall SRC frequency (Table
). Although SRC frequencies by Poisson statistics
ould not be performed for donor 4 and 6, AMD3100-
obilized MNC consistently repopulated NOD/
CID mice with high efﬁciency (Table 1).
Figure 4 shows a similar analysis performed on
uriﬁed CD34 cells isolated from the samples ob-
ained from donor 1. CD34 cells were isolated from
ach donor using magnetic adherence cell sorting and
ere 86% CD34 (range 86%-96% CD34 for
ach donor analyzed). Similar to the engraftment re-
ults obtained with donor 1 MNC, BM repopulation
as signiﬁcantly enhanced (*P  .05) in mice trans-
lanted with 5  105 CD34 cells from AMD3100
PB (3.7 0.4%, n 5) (Fig. 4A-C) compared to an
quivalent dose from G-CSF MPB (0.8  0.5%, n 
) (Fig. 4D-F). Overall engraftment results for
D34 cell transplantation into NOD/SCID mice
dose range  0.5  105-5  105 CD34 cells) were
imilar for AMD3100 (1 SRC in 7.9  104 CD34
ells, n  12) and G-CSF (1 SRC in 105 CD34 cells,
 15) mobilized MPB from donor 1 (Table 1).
uriﬁed CD34 cell transplantation from each donor
roduced more variable SRC frequencies (Table 1). phese results highlight the degree of donor-to-donor
ariability in the overall repopulating function of hu-
an CD34 cells mobilized by AMD3100 or by
-CSF.
AMD3100 MPB CD34 cells demonstrate multi-
ineage differentiation in vivo. Chimeric murine/hu-
an BM resulting from the transplantation of CD34
ells from AMD3100 and G-CSF mobilized MPB was
nalyzed for the expression of human-speciﬁc, lin-
age-restricted cell surface markers (Figure 5). Trans-
lantation of 5  105 puriﬁed CD34 cells produced
uman engraftment averaging 14.7  5.5% CD45
n  5) in a subset of mice, indicating that these cells
emonstrated extensive proliferation in vivo. Gated
uman CD45 cells (R1, Figure 5A) demonstrated
urface markers for cells of the B-lymphoid (Figure
C) and myeloid (Figure 5D) lineages, a typical de-
elopment pattern in the NOD/SCID strain. Cells
ith coexpression of CD14 with CD33 (10.2  1.0%)
nd CD20 with CD19 (15.2  4.1%) conﬁrmed the
resence of maturing human monocyte/macrophages
nd B-lymphocytes, respectively. Although human
ells expressing CD4 were detected (14.5  2.0%,
igure 5E), CD8 expression was absent, demonstrat-
ng the well-documented lack of mature T lympho-
yte development in NOD/SCID mice [36,39,40].
his pattern of predominantly B-lymphoid (
70%)
nd myeloid (
30%) cell differentiation in NOD/
CID mice was similar for transplanted G-CSF MPB
ells in previously reported studies [33,34], suggesting
hat AMD3100-mobilized HPC demonstrate normal
ematopoietic differentiation in vivo.
To assess whether the AMD3100 and G-CSF-
obilized CD34 cells maintained primitive cell phe-
otypes after transplantation, we compared engrafted
uman cells from the bone marrow of the mice for the
oexpression of the primitive cell surface marker
D34 with CD38 (Figure 5). Representative analyses
f CD45 human cells expressing these primitive cell
urface markers are shown in Figure 5F. As is typical
n the NOD/SCID mouse strain transplanted with
rimitive progenitors from any source, transplantation
f AMD3100-mobilized CD34 cells resulted primar-
ly in the generation of maturing, CD34	CD38 cells
62.9  7.3%) and committed CD34CD38 pro-
enitors (19.1  3.0%). Primitive, undifferentiated
ematopoietic cells were also represented phenotypi-
ally by CD34CD38	 (2.8  0.6%) expression.
hus, transplanted AMD3100 MPB CD34 cells
aintained primitive marker expression in trans-
lanted NOD/SCID mice. These data demonstrate
hat AMD3100 rapidly and effectively mobilized a
eterogeneous mixture of proliferative progenitors as
ell as more primitive SRC. Presumably, from the
ature of the mobilization, the mobilized cells had
xpressed the SDF-1 receptor CXCR4. Cells with the
henotype CD34/CXCR4 have been shown to
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D. A. Hess et al.406emonstrate efﬁcient BM homing after irradiation
nd to correlate well with efﬁcient neutrophil recovery
nd long-term graft survival in transplanted patients
1,5,20,23,41].
MD3100-Mobilized MNC Possess Enhanced SRC
apacity Compared to G-CSF-Mobilized Cells
Mouse engraftment data from all transplanted
onors (donors 1-6) were compiled to allow a sta-
igure 4. Detection of human cell engraftment in the BM of NOD
PB. Representative ﬂow cytometric analysis of NOD/SCID mice
-CSF mobilization (D-F) from donor 1. Mouse BM, spleen and p
ells were detected by ﬂow cytometry using the coexpression of th
requencies were 0.1% in nonengrafted controls (insets). BM en
D34 cells isolated from AMD3100 MPB (3.7  0.4%, n  5) co
ngraftment in the BM of NOD/SCID mice transplanted with AM
5, e) isolated from the same donor. Mice were considered engrafte
tatistics were performed on mouse engraftment data to calculate
ersus G-CSF mobilization in each donor.istical comparison of overall SRC function between lMD3100 and G-CSF MPB. Figure 6 demonstrates
uman engraftment in the BM of NOD/SCID mice
ransplanted with MNC (closed symbols) from
MD3100 MPB (n  61) and G-CSF MPB (n  46)
Figure 6A), or transplanted with puriﬁed CD34
ells (open symbols) from AMD3100 MPB (n  58)
nd G-CSF MPB (n  56) (Figure 6B). For the
ransplantation dose of 107 human MNC, AMD3100
PB MNC showed higher levels of human repopu-
mice transplanted with CD34 cells from AMD3100 or G-CSF
anted with 5  105 puriﬁed CD34 cells after AMD3100 (A-C) or
al blood were harvested 7-8 weeks after transplantation and human
leukocyte marker CD45 (R1) and human CD38 (R2). R1 and R2
ent was increased (**P  .01) in mice transplanted with 5  105
to G-CSF MPB (0.8  0.5%, n  5). (G) Comparison of human
MPB CD34 cells (n12, Œ) or G-CSF MPB CD34 cells (n 
frequency of human cells was0.2% CD45 and CD38. Poisson
C frequency at limiting dilution for cells derived from AMD3100/SCID
transpl
eripher
e pan-
graftm
mpared
D3100
d if the
the SRation (3.8 1.6%, n 15) compared to G-CSF MPB
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AMD3100 Mobilized CD34 Cell Repopulation 407NC (0.3  0.1%, n  7) (Figure 6A). In addition,
MD3100 MPB MNC (1 SRC in 8.7  106 MNC)
emonstrated a 3-fold increase in SRC frequency
hen directly compared to G-CSF MPB MNC (1
RC in 29.0  106 MNC), and represents a statisti-
ally signiﬁcant increase in repopulating ability for
MD3100 MPB MNC using 95% conﬁdence inter-
als (Table 1). The enhanced engraftment character-
stics were obtained despite a decrease in peripheral
lood total leukocyte and CD34 cell counts when
ompared to G-CSF mobilization.
For transplanted puriﬁed CD34 cells, AMD3100
PB demonstrated at least equivalent repopulating
evels and frequency when compared to G-CSF MPB.
he calculated SRC frequency using pooled engraft-
igure 5.Multilineage differentiation of transplanted human CD34
05 AMD3100 mobilized CD34 cells was stained with antibodie
rogenitor cells. (A) Human hematopoietic cells were selected by t
arkers CD19 and CD20 (C), myeloid cell markers CD33 and C
rogenitors by CD34 and CD38 expression (F). Data represents theent data from all donors was 1 SRC in 1.17  105 eD34 cells for AMD3100 MPB, compared with 1
RC in 1.77  105 CD34 cells for G-CSF MPB.
lthough there was considerable overlap in the 95%
onﬁdence intervals for the overall repopulating func-
ion of puriﬁed CD34 cells mobilized by these 2
gents, CD34 cells isolated after AMD3100 mobili-
ation possessed strong repopulating capacity that was
t least equivalent to CD34 cells mobilized by
-CSF.
ISCUSSION
The development of AMD3100 as a rapid and
fﬁcient mobilization agent used in allogeneic and/or
utologous transplantation procedures for hematopoi-
obilized with AMD3100. BM from a mouse transplanted with 5
arkers expressed on mature human hematopoietic and primitive
ression of CD45 (R1) and analyzed for isotype controls (B), B cell
), T cell markers CD4 and CD8 (E), and maintenance of human
SEM expression on human cells derived from murine BM (n 5). cells m
s for m
he exp
D14 (Dtic malignancies has generated considerable clinical
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D. A. Hess et al.408nterest. The beneﬁcial feature of this agent is the
apid egress of HPC from the BM into the periphery
26,42,43]. In contrast to growth factor (G-CSF)
ased mobilization, which requires up to 4 days of
epeated therapy before signiﬁcant increases in circu-
ating CD34 cells are observed, AMD3100 signiﬁ-
antly mobilized CD34 cells and HPC maximally
ithin 6 hours of single administration [26].
MD3100 was well tolerated in preliminary clinical
rials, with minimal drug toxicities and donor side
ffects, and can be successfully used in patients with
alignant disease that fail to achieve signiﬁcant mo-
igure 6. Summary of human cell repopulation in the BM of N
obilization. (A) Summary of the level of human engraftment in th
1, ) or G-CSF (n  46, ) mobilization from donors 1-6. (B) Su
ransplanted with puriﬁed CD34 cells from AMD3100 (n  58, Œ)
onor 4 was not transplanted into NOD/SCID mice. Mouse BM w
as detected by coexpression of human CD45 and human CD38. M
D45 and CD38. Poisson statistics were performed on pooled
or cells derived from AMD3100 versus G-CSF mobilization.ilization after G-CSF administration [11], although wata generated recently in murine, canine, and pri-
ate models suggests that there is no deleterious ef-
ects of prior treatment of AMD3100 on engraftment
28-30]. HPC mobilization by AMD3100 exploits in-
ibition of the SDF-1/CXCR4 axis, a key pathway
nvolved in the BM homing and migratory capacity of
ransplanted HPC [2,21,23]. Therefore, determining
hether CD34 HPC mobilized by AMD3100 will
ossess potent engraftment following transplantation
arrants further investigation with human cells in
reclinical models and clinical trials.
In this study we exploited a unique clinical design
CID mice transplanted with MNC after AMD3100 or G-CSF
f NOD/SCID mice transplanted with MNC after AMD3100 (n 
of the level of human engraftment in the BM of NOD/SCID mice
SF (n  56, e) MPB from donors 1-6. G-CSF leukapheresis from
acted 7-8 weeks after transplantation and human cell engraftment
re considered engrafted if the frequency of human cells was 0.2%
engraftment data to calculate SRC frequencies at limiting dilutionOD/S
e BM o
mmary
or G-C
as extr
ice we
mousehere healthy donors were ﬁrst leukapheresed 4-6
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AMD3100 Mobilized CD34 Cell Repopulation 409ours after AMD3100 administration, and were sub-
equently mobilized with 5 days of treatment with
-CSF 2 weeks after the initiation of the trial (Figure
). G-CSF mobilized leukapheresis was acquired as an
dditional source of HPC for patients undergoing
ransplantation with AMD3100 MPB isolated from
ealthy matched sibling donors for allogeneic trans-
lantation. A similar trial design has recently been
sed to compare endothelial progenitor function from
he same individual mobilized with AMD3100 or G-
SF treatment [44]. Additive or synergistic effects
ncurred by the use of 2 mobilization strategies in the
ame donor were minimized by the 10 day washout
eriod before G-CSF treatment [27]. Although we did
ot measure peripheral blood CD34 cell counts at
ater time points following AMD3100 injection, Liles
t al [26,27] showed that circulating CD34 progen-
tors as well as AMD3100 plasma concentration re-
urned to baseline within 24 hours. Although SRC
unction was compared on cells mobilized by
MD3100 ﬁrst and GCSF treatment second, mobili-
ation of CD34 cells by the secondary G-CSF treat-
ent (documented in Table 1) did not differ from
outine G-CSF mobilization [34]. In a similar trial,
atients administered G-CSF for 4 cycles in rapid
uccession (10-day washout period between cycles),
howed consistent mobilization of WBC and CD34
ells after each cycle, suggesting that prior condition-
ng with a mobilizing agents did not affect subsequent
obilization [45]. The major advantage of our study
esign was the ability to directly compare the NOD/
CID repopulating function of AMD3100 MPB to
hat of G-CSF MPB in a paired manner highlighting
ariation by cells isolated from the same donor.
We selected the NOD/SCID xenotransplantation
odel exclusively for the comparison of repopulating
ell capacity after AMD3100 or G-CSF mobilization.
OD/SCID mice represent the most highly studied
mmune deﬁcient animal for quantitative comparison
f HPC, and stringently engraft only primitive human
ematopoietic stem cells (scid-reconstituting cells
SRC]), whereas not engrafting with more committed
rogenitors that contribute to engraftment in the
OD/SCID/B2M null strain [33,36]. Total leukocyte
nd CD34 cells/L leukapheresed were 2-fold lower
han the levels obtained by 5-day administration of
-CSF in the same individual. At the same time,
MD3100 mobilized MNC demonstrated an overall
-fold increase in repopulating frequency after trans-
lantation into immune-deﬁcient NOD/SCID mice.
herefore, AMD3100-mobilized leukapheresis MNC
ollected 4-6 hours after drug administration contained a
igher frequency of SRC on a cell-per-cell basis, and at
east equivalent total SRC numbers, compared to G-
SF-mobilized leukapheresis products. In addition,
rug inhibition of CXCR4 appeared short-lived, and did bot signiﬁcantly interfere with the overall engraftment of
uman cells in the murine BM.
For transplanted puriﬁed CD34 cells, AMD3100
PB demonstrated at least equivalent repopulating
requency compared to G-CSF MPB. The calculated
RC frequency using pooled engraftment data from
ll donors was only modestly increased, with consid-
rable overlap in the 95% conﬁdence intervals
Table 1). Our transplantation data produced 1 SRC in
.17 105 CD34 cells for AMD3100MPB, compared
ith 1 SRC in 1.77  105 CD34 cells for G-CSF
PB. These frequencies correspond with a similar
omparison performed by Broxmeyer et al [29] using
onpaired subjects. The Broxmeyer group achieved an
verall repopulating frequency of 12.68  6.36 SRC
er 106 CD34 cells (approximately 1 SRC in 0.8 
05 cells) for AMD3100 MPB versus 3.35 2.04 SRC
er 106 CD34 cells (approximately 1 SRC in 3 105
ells) for G-CSF MPB. This group also reported an
verall 4.5 3.4-fold increase in SRC frequency from
MD3100 leukapheresis products, compared to G-
SF MPB [29]. In paired subjects, we observed a
odest (2-fold) increase in SRC frequency compar-
ng AMD3100 and G-CSF mobilized CD34 cells.
he discrepancy observed within these studies may be
xplained by inherent differences in trial design in-
luding donor characteristics and variability in
MD3100 and G-CSF dose, or by variance in NOD/
CID colony housing, and detection methods for hu-
an engraftment. Furthermore, the enhanced SRC
apacity elicited by AMD3100 MPB MNC in combi-
ation with the similar SRC frequency observed for
D34 cells may be partially explained by the in-
reased number of circulating myeloid cells mobilized
y G-CSF. AMD3100 mobilized CD34 cells may
lso possess repopulating characteristics different than
D34 cells mobilized with G-CSF [29]. AMD3100
ay also mobilize repopulating cells with alternate
henotypes that do not express CD34. Further char-
cterization of repopulating cells mobilized by
MD3100 using non-CD34-expressing stem cells or
lternate methods of HPC puriﬁcation, such as the
se of aldehyde dehydrogenase or ABCG2 transporter
ctivity, are clearly warranted [31,46].
It is also possible that non-CD34 engraftment-
nhancing populations such as mesenchymal stem
ells or T lymphoid facilitator cells could be mobilized
t higher levels by AMD3100, causing the more dra-
atic increase in reconstitution capacity from the
MD3100 MPB MNC in comparison to the G-CSF
PB MNC. Future studies should employ AMD3100
s a valuable source for the isolation of alternate cell
ypes putatively released into the circulation after mo-
ilization. CXCR4 cells with endothelial progenitor
r mesenchymal functions may be rapidly mobilized
y AMD3100, and these cells may be exploited in
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D. A. Hess et al.410uture development of cell therapies for a wide variety
f tissue injury or disease.
In summary, AMD3100 MPB represents a rapidly
btained and highly repopulating source of hemato-
oietic progenitors suitable for clinical transplantation
rocedures. In allogeneic transplantation protocols,
MD3100 administration is noninvasive and effective
or the mobilization of peripheral blood stem cells
rom healthy donors in a same-day procedure, without
he associated bone pain or pleiotropic effects on neu-
rophils that are evident after G-CSF treatment. Fur-
her clinical evaluation should establish AMD3100,
lone or in combination with G-CSF, as a primary
ethod for the mobilization of HPC for transplanta-
ion.
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